<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07617R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006523</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Cancer Genetics</subject><subject>Oncology/Prostate Cancer</subject><subject>Public Health and Epidemiology/Epidemiology</subject></subj-group></article-categories><title-group><article-title>Genetic Polymorphisms of Estrogen Receptors &#x003b1; and &#x003b2; and the Risk of Developing Prostate Cancer</article-title><alt-title alt-title-type="running-head">Prostate Cancer Polymorphism</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chae</surname><given-names>Young Kwang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Han-Yao</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Strickland</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoffman</surname><given-names>Sandra C.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Helzlsouer</surname><given-names>Kathy</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania; United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Outcomes Research and Management, Merck &#x00026; Co., West Point, Pennsylvania, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>The Prevention and Research Center, Mercy Medical Center, Baltimore, Maryland, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Bridger</surname><given-names>Joanna Mary</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Brunel University, United Kingdom</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>youngkwang.chae@gmail.com</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: YKC HYH. Performed the experiments: YKC PS SCH KH. Analyzed the data: YKC. Contributed reagents/materials/analysis tools: YKC. Wrote the paper: YKC.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>8</month><year>2009</year></pub-date><volume>4</volume><issue>8</issue><elocation-id>e6523</elocation-id><history><date date-type="received"><day>4</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2009</year></date></history><permissions><copyright-statement>Chae et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><p>Estrogen may be involved in the development of prostate cancer. The association between genetic polymorphisms of estrogen receptors &#x003b1; (ESR1) and &#x003b2; (ESR2) and prostate cancer risk was examined in a nested case-control study in Washington County, Maryland. Incident prostate cancer cases (n&#x0200a;&#x0003d;&#x0200a;269) were matched to one or two controls (n&#x0200a;&#x0003d;&#x0200a;440) by age, sex, race, and date of blood donation. Associations between estrogen receptor genotypes or dietary intake and the development of prostate cancer were examined in conditional logistic regression models. Results from this study showed that six single base-pair polymorphisms (SNPs) of ESR1 (rs1801132, rs2077647, rs746432, rs2273206, rs851982, rs2228480) and four SNPs of ESR2 (rs4986938, rs928554, rs8018687, rs number not available for ESR2 5696 bp 3&#x02032; of STP A&#x0003e;G) were not significantly associated with prostate cancer risk, either by allelic or genotypic frequencies. However, an interactive association with BMI was observed in the relationship between prostate cancer risk and genotypes of ESR2 38 bp 3&#x02032; of STP G&#x0003e;A (rs4986938) (p&#x0200a;&#x0003d;&#x0200a;0.031). An interaction between intake level of phytoestrogen and genotypes of ESR1 Ex1-192G&#x0003e;C (rs746432) and between intake level of phytoestrogen and genotypes of ESR1 Ex8&#x0002b;229G&#x0003e;A (rs2228480) and risk of prostate cancer was observed (p&#x0200a;&#x0003d;&#x0200a;0.0009 and p&#x0200a;&#x0003d;&#x0200a;0.044, respectively). In conclusion, selected genetic polymorphisms of ESR1 and ESR2, overall, were not associated with prostate cancer risk. However, a variation in risk by BMI and phytoestrogen intake was implicated.</p></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The development of prostate cancer may be hormone-dependent <xref ref-type="bibr" rid="pone.0006523-Gann1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Ekman1">&#x0005b;2&#x0005d;</xref>. For example, androgens are important for normal and hyperplastic prostate growth. Both testosterone and dihydrotestosterone (DHT) induced prostatic adenocarcinoma in rat models <xref ref-type="bibr" rid="pone.0006523-Noble1">&#x0005b;3&#x0005d;</xref>. Anti-androgen therapy or orchiectomy has been used to treat metastatic prostate cancer <xref ref-type="bibr" rid="pone.0006523-Singer1">&#x0005b;4&#x0005d;</xref>. Estrogen as well as androgen may play an important role in the carcinogenesis of prostate cells <xref ref-type="bibr" rid="pone.0006523-Ricke1">&#x0005b;5&#x0005d;</xref>. It was initially thought that estrogens mediate their action through estrogen receptor &#x003b1; (ESR1). Estrogen receptor &#x003b2; (ESR2) was later identified to be involved in the process <xref ref-type="bibr" rid="pone.0006523-Kuiper1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Mosselman1">&#x0005b;7&#x0005d;</xref>. Although these two receptors share 47&#x00025; structural similarities, they can be differentiated by their physiological properties <xref ref-type="bibr" rid="pone.0006523-Kuiper1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Kuiper2">&#x0005b;8&#x0005d;</xref>. While ESR1 is mainly localized in the prostatic stroma <xref ref-type="bibr" rid="pone.0006523-Bashirelahi1">&#x0005b;9&#x0005d;</xref>, ESR2 is mostly located in the prostatic epithelium <xref ref-type="bibr" rid="pone.0006523-Prins1">&#x0005b;10&#x0005d;</xref>. ESR1 plays an essential role in prostate development <xref ref-type="bibr" rid="pone.0006523-Yager1">&#x0005b;11&#x0005d;</xref> and is found to be related to estrogen-induced prostatic squamous metaplasia <xref ref-type="bibr" rid="pone.0006523-Risbridger1">&#x0005b;12&#x0005d;</xref>. Also, its expression at tumor level negatively correlates with prostate cancer survival <xref ref-type="bibr" rid="pone.0006523-Fujimura1">&#x0005b;13&#x0005d;</xref>. On the other hand, ESR2 is thought to be an important regulator of prostate function <xref ref-type="bibr" rid="pone.0006523-Koehler1">&#x0005b;14&#x0005d;</xref>, especially as a potential &#x0201c;brake&#x0201d; to androgen-driven proliferation <xref ref-type="bibr" rid="pone.0006523-Fujimura1">&#x0005b;13&#x0005d;</xref>.</p><p>Several studies have suggested a relationship between these two receptors and prostate cancer <xref ref-type="bibr" rid="pone.0006523-Signoretti1">&#x0005b;15&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006523-Lee1">&#x0005b;21&#x0005d;</xref>. For example, exposure to high levels of estrogen in uteri may lead to smaller adult prostates that are poorly sensitive to androgen for the development of hyperplasia, inflammation and dysplasia <xref ref-type="bibr" rid="pone.0006523-Prins2">&#x0005b;16&#x0005d;</xref>. This genetic imprinting is found to be mediated by ESR1 <xref ref-type="bibr" rid="pone.0006523-Prins2">&#x0005b;16&#x0005d;</xref>. Other studies have consistently found that ESR2 is expressed in metastatic prostate cancer cells <xref ref-type="bibr" rid="pone.0006523-Leav1">&#x0005b;17&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006523-Lai1">&#x0005b;19&#x0005d;</xref>. Accordingly, phytoestrogens, chemicals produced by plants that mimic estrogen effects, may act like ESR2 agonist. It has been hypothesized that phytoestrogen may be protective against prostate cancer <xref ref-type="bibr" rid="pone.0006523-Adlercreutz1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Lee1">&#x0005b;21&#x0005d;</xref>.</p><p>Genetic polymorphisms of the ESR1 and ESR2 have been reported to be associated with prostate cancer risk <xref ref-type="bibr" rid="pone.0006523-Tanaka1">&#x0005b;22&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006523-Hedelin1">&#x0005b;34&#x0005d;</xref>. However, no biological functional studies have been published to support the epidemiologic findings, and analyses of gene-environment interactions were rarely performed. Identifying the environmental factors that may modify the relationship between genetic polymorphisms and disease risk may provide a clue to possible functions of the genetic polymorphisms or to the locations of functional SNPs. Body mass index (BMI) may be a proxy indicator for the relative amount of body fat, which is a major source of estrogen production in men <xref ref-type="bibr" rid="pone.0006523-Schneider1">&#x0005b;35&#x0005d;</xref>. Availability of estrogen in the body may affect the sensitivity of estrogen receptors, possibly leading to a different risk profile for prostate carcinogenesis. On the other hand, phytoestrogen, rich in legumes, may stimulate or modulate estrogen receptors, particularly for ESR2 <xref ref-type="bibr" rid="pone.0006523-Kuiper3">&#x0005b;36&#x0005d;</xref>.</p><p>A nested case-control study was conducted to examine the associations between selective polymorphisms of ESR 1, ESR2 genes and the risk of developing prostate cancer in a community-based cohort in Washington County, Maryland. Exploratory analyses examined how the ESR1 and ESR2 SNPs of interest modified the association between BMI/phytoestrogen and prostate cancer risk and also how BMI and phytoestrogen altered the association between the ESR1 and ESR2 SNPs of interest and prostate cancer risk.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study population</title><p>CLUE II was a slogan of the second research campaign, &#x0201c;Give us a CLUE to cancer and Heart Disease&#x0201d;, conducted in Washington County, Maryland in 1989. The participants were 10,456 men and 14,625 women (total of 25,081). Approximately 30&#x00025; of the Washington County adult population participated. Mobile office trailers were utilized to collect specimen. 20 ml of blood from each participant was put into 20 ml vacutainer. In addition to plasma aliquots, white blood cells and a sample with a vitamin C preservative were stored at &#x02212;70&#x000b0;C. Buffy coats from the samples were used as a source of the genotyping analysis.</p><p>Study participants provided data on education, cigarette smoking (never, former, current), height, weight, medication use, and vitamin use in the year prior to questionnaire administration. They also filled out a brief food frequency questionnaire <xref ref-type="bibr" rid="pone.0006523-The1">&#x0005b;37&#x0005d;</xref> that included questions about the serving size and frequency of intake of 61 food items. The annual loss-to-follow-up in the cohort was less than 1 percent.</p><p>A written informed consent to the participation in the research campaign was obtained from each participant at the time of blood donation. This study was approved by the institutional review board of the Johns Hopkins Bloomberg School of Public Health.</p></sec><sec id="s2b"><title>Case ascertainment and control selection</title><p>Prostate cancer incident cases (International Classification of Diseases, 9th revision, code 185) were identified through linkage to the Washington County Cancer Registry and since 1992, also to the Maryland State Cancer Registry. All cases were confirmed pathologically (n&#x0200a;&#x0003d;&#x0200a;269). Stages and grades were described according to American Joint Committee on Cancer/Tumor Node Metastasis (TNM) system and Gleason's Score system, respectively.</p><p>Cases were defined as participants who developed primary prostate cancer during the follow up period from 1989 to 2002. Each prostate cancer case was individually matched with one or two controls on age (&#x000b1;1 year), gender, ethnicity, and date of blood donation. One-to-one and one-to-two matching was done for 36&#x00025; and 64&#x00025;, respectively, of the cases. Each control was selected from the CLUE II cohort, not known to have cancer except for basal or squamous cell skin cancer and not known to have died, at the time when the corresponding case was diagnosed.</p></sec><sec id="s2c"><title>Genotyping</title><p>Heparinized blood samples were centrifuged at 1500 g for 30 minutes at room temperature within 6 hours of collection. Then they were separated into plasma, buffy coat, and red blood cells and were frozen at &#x02212;70&#x000b0;C within 24 hours of collection. Genetic polymorphisms of estrogen receptor &#x003b1; (ESR1) and estrogen receptor &#x003b2; (ESR2) were determined on DNA samples extracted from the preserved participants' buffy coat specimens. The buffy coat remained frozen till DNA extraction was done. The alkaline lysis method was used for the DNA extraction procedure. All genotypings were carried out using TaqMan&#x000ae; assays (Applied Biosystems, Foster city, CA, USA). Laboratory researchers handling samples were masked to disease status.</p><p>Candidate single nucleotide polymorphisms (SNPs) were chosen based on the following criteria: (a) the allele frequency of over five percent in published literature or databases, recommended by the National Cancer Institute <xref ref-type="bibr" rid="pone.0006523-Packer1">&#x0005b;38&#x0005d;</xref>, (b) validated allele substitutions, and/or (c) functional changes linked with allele substitution reported in the literature.</p><p>For describing SNP sequence variations, we adapted the recommendation from a Nomenclature Working Group <xref ref-type="bibr" rid="pone.0006523-denDunnen1">&#x0005b;39&#x0005d;</xref>. Among the ESR1 SNPs, four SNPs including Ex4-122C&#x0003e;G, Ex1&#x0002b;392T&#x0003e;C, Ex1-192G&#x0003e;C, and Ex8&#x0002b;229G&#x0003e;A were in the coding region. The rest of the ESR1 SNPs were either in the non-coding region prior to ATG translation initiating codon (-104062C&#x0003e;T), or in the intron 6 region (IVS6&#x0002b;52G&#x0003e;T). All of the ESR2 SNPs were in the non-coding region after the translation terminating codon (38 bp 3&#x02032; of STP G&#x0003e;A, 5659 bp 3&#x02032; of STP A&#x0003e;G, 5696 bp 3&#x02032; of STP A&#x0003e;G, 5772 bp 3&#x02032; of STP A&#x0003e;G). Ten selected SNPs were genotyped in both cases and controls. Among cases, 13.1&#x00025; (35/269) were missing any one genotype and among controls, 10.5&#x00025; (46/440). Average missing rate for any one genotype was around 18&#x00025;.(I have erased the accuracy part.)</p></sec><sec id="s2d"><title>Statistical Analysis</title><p>Baseline characteristics between cases and controls were compared by conditional logistic regression models for categorical variables (<xref ref-type="table" rid="pone-0006523-t001">Table 1</xref>). Based on self-reported height and weight at the time of blood donation, we calculated BMI as kilogram per square meter. Family history was identified by self report on the prostate cancer history of grandfathers, fathers and brothers. Dietary intake of fat, energy, phytoestrogen, and calcium was estimated by summing the product of the frequency of consumption of each food, the reported serving size, and the energy or nutrient content per serving. Total phytoestrogen intake was computed based on legume consumption. Isoflavone (phytoestrogen) contents were estimated for beans (pinto, lima, kidney, and other beans, possibly including soy), peas, and peanuts using USDA-Iowa State University Database on the Isoflavone Content of Foods, 1999 <xref ref-type="bibr" rid="pone.0006523-1">&#x0005b;40&#x0005d;</xref>. All quartile cut-offs used were based on the data in the control group. High/low phytoestrogen intake cut-off was the median level of intake in the control group. To deal with missing data for dietary (average of 30&#x00025; missing) in calculating the total isoflavone intake, imputation analysis was performed, inserting zero or median in place of missing data, both of which did not affect the overall results.</p><table-wrap id="pone-0006523-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006523.t001</object-id><label>Table 1</label><caption><title>Characteristics of prostatic cancer cases and matched controls in the CLUE 2 cohort, 1989.</title></caption><alternatives><graphic id="pone-0006523-t001-1" xlink:href="pone.0006523.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">case subjects (n&#x0200a;&#x0003d;&#x0200a;269)</td><td align="left" rowspan="1" colspan="1">control subjects (n&#x0200a;&#x0003d;&#x0200a;440)</td><td align="left" rowspan="1" colspan="1">matched odds ratio</td><td align="left" rowspan="1" colspan="1">95&#x00025; confidence interval</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age, y, mean(SE)</bold></td><td align="left" rowspan="1" colspan="1">64.1( 9.0)</td><td align="left" rowspan="1" colspan="1">64.7(8.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Race, Black, n, (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">6(2.23)</td><td align="left" rowspan="1" colspan="1">11(2.50)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Education level, y, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0003c;12</bold></td><td align="left" rowspan="1" colspan="1">27.1</td><td align="left" rowspan="1" colspan="1">34.1</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0200a;&#x0003d;&#x0200a;12</bold></td><td align="left" rowspan="1" colspan="1">42.8</td><td align="left" rowspan="1" colspan="1">37.3</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1">0.94, 2.02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0003e;12</bold></td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1">28.6</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">0.84,1.84</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Cigarette smoking, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;never</bold></td><td align="left" rowspan="1" colspan="1">39.8</td><td align="left" rowspan="1" colspan="1">39.3</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;former</bold></td><td align="left" rowspan="1" colspan="1">51.7</td><td align="left" rowspan="1" colspan="1">50.2</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">1.75,1.41</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;current</bold></td><td align="left" rowspan="1" colspan="1">8.5</td><td align="left" rowspan="1" colspan="1">10.5</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">0.44,1.40</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>BMI at baseline, kg/m<sup>2</sup>, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0003c;24.9</bold></td><td align="left" rowspan="1" colspan="1">33.1</td><td align="left" rowspan="1" colspan="1">30.2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;25&#x02013;29.9</bold></td><td align="left" rowspan="1" colspan="1">52.4</td><td align="left" rowspan="1" colspan="1">55.9</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">0.59,1.19</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0003e;&#x0200a;&#x0003d;&#x0200a;30</bold></td><td align="left" rowspan="1" colspan="1">14.5</td><td align="left" rowspan="1" colspan="1">13.9</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.57,1.57</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>BMI at age 21, kg/m<sup>2</sup>, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0003c;24.9</bold></td><td align="left" rowspan="1" colspan="1">80.9</td><td align="left" rowspan="1" colspan="1">78.2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;25&#x02013;29.9</bold></td><td align="left" rowspan="1" colspan="1">16.1</td><td align="left" rowspan="1" colspan="1">19.8</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.53,1.18</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;&#x0003e;&#x0200a;&#x0003d;&#x0200a;30</bold></td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">0.42,3.34</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Vitamin supplement use, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;multivitamin regular use</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">23.6</td><td align="left" rowspan="1" colspan="1">20.2</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.71,1.73</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;ever vitamin C use</bold><xref ref-type="table-fn" rid="nt102">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">37.6</td><td align="left" rowspan="1" colspan="1">34.6</td><td align="left" rowspan="1" colspan="1">1.04</td><td align="left" rowspan="1" colspan="1">0.75,1.46</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;ever vitamin D use</bold><xref ref-type="table-fn" rid="nt102">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">25.2</td><td align="left" rowspan="1" colspan="1">21.6</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.81,1.69</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;ever vitamin E use</bold><xref ref-type="table-fn" rid="nt102">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">34.8</td><td align="left" rowspan="1" colspan="1">33.1</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">0.72,1.41</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Family history</bold><xref ref-type="table-fn" rid="nt103">&#x02021;</xref><bold>, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;no</bold></td><td align="left" rowspan="1" colspan="1">58.7</td><td align="left" rowspan="1" colspan="1">63.4</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;yes</bold></td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">1.69</td><td align="left" rowspan="1" colspan="1">0.82,3.48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;missing</bold></td><td align="left" rowspan="1" colspan="1">32.7</td><td align="left" rowspan="1" colspan="1">31.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Dietary intake of fat, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;1st quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">23.4</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;2nd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">18.6</td><td align="left" rowspan="1" colspan="1">23.0</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.50,1.27</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;3rd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">24.5</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">0.58,1.50</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;4th quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">26.4</td><td align="left" rowspan="1" colspan="1">23.0</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0.68,1.70</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;missing</bold></td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Dietary intake of total calories, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;1st quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">20.1</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;2nd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">25.3</td><td align="left" rowspan="1" colspan="1">23.0</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">0.77,1.93</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;3rd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">21.6</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">0.63,1.63</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;4th quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">26.0</td><td align="left" rowspan="1" colspan="1">23.0</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">0.78,1.20</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;missing</bold></td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Dietary intake of calcium, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;1st quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">20.1</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;2nd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">24.9</td><td align="left" rowspan="1" colspan="1">23.0</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.70,1.78</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;3rd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">26.0</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">0.78,1.92</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;3rd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">21.9</td><td align="left" rowspan="1" colspan="1">23.0</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0.66,1.75</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;missing</bold></td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Dietary intake of phytoestrogen, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;1st quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">19.7</td><td align="left" rowspan="1" colspan="1">17.5</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;2nd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">17.8</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.43,1.39</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;3rd quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">0.31,1.09</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;4th quartile</bold><xref ref-type="table-fn" rid="nt105">&#x0041f;</xref></td><td align="left" rowspan="1" colspan="1">21.2</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1">0.97</td><td align="left" rowspan="1" colspan="1">0.55,1.71</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;missing</bold></td><td align="left" rowspan="1" colspan="1">27.9</td><td align="left" rowspan="1" colspan="1">30.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Stage of disease at diagnosis, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>0</bold></td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1">14.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1">32.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1">18.2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4</bold></td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>missing</bold></td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Grade of disease at diagnosis</bold><xref ref-type="table-fn" rid="nt104">&#x000a7;</xref><bold>, &#x00025;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1">7.8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1">64.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1">7.4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>missing</bold></td><td align="left" rowspan="1" colspan="1">20.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Case/control, &#x00025;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;one/one</bold></td><td align="left" rowspan="1" colspan="1">36.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>&#x02003;one/two</bold></td><td align="left" rowspan="1" colspan="1">64.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>&#x0002a;regular users compared with nonusers and non-regular users among responder of the questionnaire.</p></fn><fn id="nt102"><label>&#x02020;</label><p>ever-users compared with nonusers among responders of the questionnaire.</p></fn><fn id="nt103"><label>&#x02021;</label><p>prostate cancer of grandfather, father, and brothers.</p></fn><fn id="nt104"><label>&#x000a7;</label><p>Grade: 1(Gleason score 2&#x02013;4, well differentiated), 2(Gleason score 5&#x02013;7, moderately differentiated), 3(Gleason score 8&#x02013;10, poorly differentiated).</p></fn><fn id="nt105"><label>&#x0041f;</label><p>All quartiles are derived from controls: 1) total caloric intake (n&#x0200a;&#x0003d;&#x0200a;652) quartile cut off: 1107.8, 1438.4, 1861.8 Cal/d. 2) fat intake (n&#x0200a;&#x0003d;&#x0200a;652) quartile cutoff: 42.1, 59.0, 78.2 Cal/d. 3) calcium intake (n&#x0200a;&#x0003d;&#x0200a;652) quartile cutoff: 424.0, 616.4, 878.7 mg/d 4) phytoestrogen intake (n&#x0200a;&#x0003d;&#x0200a;499) quartile cut off: 1.35, 2.71, 4.14 mg/mo.</p></fn></table-wrap-foot></table-wrap><p>Association between estrogen receptor genotypes and the development of prostate cancer was examined in conditional logistic regression analyses. Odds ratios and the corresponding 95&#x00025; confidence intervals were derived from three different genetic effect models, including dominant, recessive and additive models. Additionally, analyses were stratified by cancer stage and grade.</p><p>Gene-environment interaction associations of BMI or dietary phytoestrogen (isoflavone) intake on the relationship between prostate cancer risk and estrogen receptor gene genotypes were assessed by both stratification analyses and the likelihood ratio test (LRT) that compared the conditional logistic regression models with and without interaction terms. Associations between ESR1 and ESR2 genotypes and prostate cancer risk were evaluated in strata of three BMI categories and separately, strata of high/low phytoestrogen intake, by unconditional logistic regression with adjustment for age and race. The same method was used to assess the associations between BMI or dietary phytoestrogen intake and prostate cancer risk in strata of estrogen receptor genotypes, with adjustment for caloric intake in the analysis on phytoestrogen intake, age, and race. For BMI, test for trend was performed on the median values in each three categories. For genotypes, the additive model was assumed in the tests for trend. All p-values were derived from two-sided test and were considered to be statistically significant if less than 0.05. All statistical analyses were performed using STATA Statistical Software, 9.0 (Stata Corporation, College Station, TX, 2005).</p></sec></sec><sec id="s3"><title>Results</title><p>Cases and controls were comparable with respect to age, race, education, history of cigarette smoking, vitamin use, and dietary intakes of fat, total calories, phytoestrogen, and calcium (<xref ref-type="table" rid="pone-0006523-t001">Table 1</xref>). Among the 188 cases whose disease stages were determined, 129 had localized disease, defined as TNM stage 0, 1 or 2, and 59 had advanced disease, defined as TNM stage 3 or 4 (<xref ref-type="table" rid="pone-0006523-t001">Table 1</xref>). Hardy-Weinberg equilibrium was tested for Caucasians in controls, who were 263 (94&#x00025;) and 429 (89&#x00025;) in each group. All the SNPs were in Hardy-Weinberg equilibrium except for ESR2 5659 bp 3&#x02032; of STP A&#x0003e;G among cases and ESR1 IVS6&#x0002b;52G&#x0003e;T, ESR1 -104062C&#x0003e;T, 5659 bp 3&#x02032; of STP A&#x0003e;G among controls (<xref ref-type="supplementary-material" rid="pone.0006523.s001">Table S1</xref>). Observed major allele frequencies of ESR SNPs from the CLUE cohort were compared with SNP500 or dbSNP data if available, separately for Caucasians and African Americans. Among the eight SNPs compared, no statistically significant difference was found with the exception of ESR1 Ex8&#x0002b;229G&#x0003e;A for Caucasians (<xref ref-type="supplementary-material" rid="pone.0006523.s002">Table S2</xref>).</p><p><xref ref-type="table" rid="pone-0006523-t002">Table 2</xref> presents odd ratio estimates of prostate cancer risk for each genotype of estrogen receptor gene SNP. In dominant, recessive, and additive models, no statistically significant association was found between the SNPs and prostate cancer risk. In addition, no significant trend was found in the number of alleles with respect to prostate cancer risk. Of all ten SNPs, only ESR1 Ex4-122C&#x0003e;G was consistently associated with increased prostate cancer risk across all subgroups defined by stages and grades of the cancer (<xref ref-type="table" rid="pone-0006523-t002">Table 2</xref>). However, none of the results were statistically significant. Among advanced prostate cancer cases, for ESR1, C allele in Ex1&#x0002b;392T&#x0003e;C was associated with a statistically significant decreased risk of prostate cancer. The T allele in IVS6&#x0002b;52G&#x0003e;T was associated with an increased risk of prostate cancer but the trend in risk with burden of T alleles was not statisticially significant. For ESR2, A allele in 38 bp 3&#x02032; of STP G&#x0003e;A and A allele in 5659 bp 3&#x02032; of STP A&#x0003e;G were associated with an increased risk of advanced prostate cancer but association were not statistically significant. (<xref ref-type="table" rid="pone-0006523-t002">Table 2</xref>).</p><table-wrap id="pone-0006523-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006523.t002</object-id><label>Table 2</label><caption><title>The genotype frequencies of ESR1,2 polymorphisms and prostate cancer risk.</title></caption><alternatives><graphic id="pone-0006523-t002-2" xlink:href="pone.0006523.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td colspan="2" align="left" rowspan="1">Frequency</td><td colspan="8" align="left" rowspan="1">Odds Ratio (95&#x00025;CI)</td></tr><tr><td align="left" rowspan="1" colspan="1">(dbSNP ID)</td><td align="left" rowspan="1" colspan="1">No. Cases (&#x00025;)</td><td align="left" rowspan="1" colspan="1">No. Controls (&#x00025;)</td><td align="left" rowspan="1" colspan="1">All Cases (269)</td><td align="left" rowspan="1" colspan="1">LocalizedStage<xref ref-type="table-fn" rid="nt109">&#x000a7;</xref> (129)</td><td align="left" rowspan="1" colspan="1">Advanced Stage<xref ref-type="table-fn" rid="nt109">&#x000a7;</xref> (59)</td><td align="left" rowspan="1" colspan="1">Low Grade<xref ref-type="table-fn" rid="nt110">&#x0041f;</xref> (134)</td><td align="left" rowspan="1" colspan="1">High Grade<xref ref-type="table-fn" rid="nt110">&#x0041f;</xref> (57)</td><td align="left" rowspan="1" colspan="1">Dominant Model</td><td align="left" rowspan="1" colspan="1">Recessive Model</td><td align="left" rowspan="1" colspan="1">Additive Model</td></tr></thead><tbody><tr><td colspan="11" align="left" rowspan="1"><bold>ESR1 Ex4-122C&#x0003e;G (rs1801132)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">128 (47.6)</td><td align="left" rowspan="1" colspan="1">230 (52.3)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/G</bold></td><td align="left" rowspan="1" colspan="1">80 (29.7)</td><td align="left" rowspan="1" colspan="1">127 (28.9)</td><td align="left" rowspan="1" colspan="1">1.08 (0.75,1.55)</td><td align="left" rowspan="1" colspan="1">1.05 (0.61,1.80)</td><td align="left" rowspan="1" colspan="1">1.22 (0.58,2.57)</td><td align="left" rowspan="1" colspan="1">1.16 (0.76,1.78)</td><td align="left" rowspan="1" colspan="1">1.07 (0.22,5.11)</td><td align="left" rowspan="1" colspan="1">1.15 (0.81,1.62)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.17 (0.89,1.56)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">13 (4.8)</td><td align="left" rowspan="1" colspan="1">12(2.7)</td><td align="left" rowspan="1" colspan="1">1.73 (.78,3.85)</td><td align="left" rowspan="1" colspan="1">2.33 (0.81,6.67)</td><td align="left" rowspan="1" colspan="1">1.65 (0.39,6.92)</td><td align="left" rowspan="1" colspan="1">1.30 (0.47,3.58)</td><td align="left" rowspan="1" colspan="1">2.32 (0.37,14.34)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.69 (0.77,3.75)</td><td align="left" rowspan="1" colspan="1">1.37 (0.79,2.43)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>missing</bold></td><td align="left" rowspan="1" colspan="1">48 (17.8)</td><td align="left" rowspan="1" colspan="1">71(16.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.257</td><td align="left" rowspan="1" colspan="1">0.230</td><td align="left" rowspan="1" colspan="1">0.422</td><td align="left" rowspan="1" colspan="1">0.412</td><td align="left" rowspan="1" colspan="1">0.414</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR1 Ex1&#x0002b;392T&#x0003e;C (rs2077647)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">64 (23.79)</td><td align="left" rowspan="1" colspan="1">102 (23.2)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/C</bold></td><td align="left" rowspan="1" colspan="1">104 (38.7)</td><td align="left" rowspan="1" colspan="1">173 (39.3)</td><td align="left" rowspan="1" colspan="1">0.92 (0.60,1.41)</td><td align="left" rowspan="1" colspan="1">0.97 (0.52,1.81)</td><td align="left" rowspan="1" colspan="1">0.45 (0.18,1.14)</td><td align="left" rowspan="1" colspan="1">0.87 (0.53,1.44)</td><td align="left" rowspan="1" colspan="1">1.22 (0.23,6.42)</td><td align="left" rowspan="1" colspan="1">0.90 (0.61,1.34)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.93 (0.74,1.19)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">51 (18.96)</td><td align="left" rowspan="1" colspan="1">94 (21.36)</td><td align="left" rowspan="1" colspan="1">0.87 (0.54,1.41)</td><td align="left" rowspan="1" colspan="1">1.13 (0.58,2.24)</td><td align="left" rowspan="1" colspan="1">0.27 (0.09,0.80)</td><td align="left" rowspan="1" colspan="1">0.85 (0.48,1.50)</td><td align="left" rowspan="1" colspan="1">0.41 (0.06,2.59)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.92 (0.61,1.38)</td><td align="left" rowspan="1" colspan="1">0.86 (0.55,1.42)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>missing</bold></td><td align="left" rowspan="1" colspan="1">50 (18.6)</td><td align="left" rowspan="1" colspan="1">71(16.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.582</td><td align="left" rowspan="1" colspan="1">0.686</td><td align="left" rowspan="1" colspan="1">0.515</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR1 Ex1-192G&#x0003e;C (rs746432)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">177 (65.8)</td><td align="left" rowspan="1" colspan="1">301 (68.41)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/C,C/C</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">37 (13.8)</td><td align="left" rowspan="1" colspan="1">69(15.7)</td><td align="left" rowspan="1" colspan="1">0.96 (0.60.1.55)</td><td align="left" rowspan="1" colspan="1">1.03 (0.55,1.94)</td><td align="left" rowspan="1" colspan="1">0.75 (0.20,2.76)</td><td align="left" rowspan="1" colspan="1">0.98 (0.54,1.79)</td><td align="left" rowspan="1" colspan="1">2.65 (0.49,14.28)</td><td align="left" rowspan="1" colspan="1">0.96 (0.60.1.55)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Missing</bold></td><td align="left" rowspan="1" colspan="1">55 (20.5)</td><td align="left" rowspan="1" colspan="1">70 (15.91)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.872</td><td align="left" rowspan="1" colspan="1">0.915</td><td align="left" rowspan="1" colspan="1">0.663</td><td align="left" rowspan="1" colspan="1">0.959</td><td align="left" rowspan="1" colspan="1">0.257</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR1 IVS6&#x0002b;52G&#x0003e;T (rs2273206)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">171 (63.6)</td><td align="left" rowspan="1" colspan="1">299 (68.0)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/T</bold></td><td align="left" rowspan="1" colspan="1">48 (17.8)</td><td align="left" rowspan="1" colspan="1">72 (16.4)</td><td align="left" rowspan="1" colspan="1">1.19 (0.79,1.78)</td><td align="left" rowspan="1" colspan="1">1.00 (0.54,1.84)</td><td align="left" rowspan="1" colspan="1">1.63 (0.74,3.55)</td><td align="left" rowspan="1" colspan="1">0.87 (0.52,1.43)</td><td align="left" rowspan="1" colspan="1">1.73 (0.28,10.58)</td><td align="left" rowspan="1" colspan="1">1.21 (0.82,1.79)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.19 (0.84,1.68)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">5 (1.9)</td><td align="left" rowspan="1" colspan="1">8 (1.8)</td><td align="left" rowspan="1" colspan="1">1.41 (0.44,4.49)</td><td align="left" rowspan="1" colspan="1">1.00 (0.18,5.50)</td><td align="left" rowspan="1" colspan="1">5.58 (0.56,55.10)</td><td align="left" rowspan="1" colspan="1">1.32 (0.29,5.96)</td><td align="left" rowspan="1" colspan="1">2.00 (0.13,31.98)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.35 (0.43,4.27)</td><td align="left" rowspan="1" colspan="1">1.42 (0.71,2.82)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Missing</bold></td><td align="left" rowspan="1" colspan="1">45 (16.7)</td><td align="left" rowspan="1" colspan="1">61 (13.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.326</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1">0.770</td><td align="left" rowspan="1" colspan="1">0.451</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR1 -104062C&#x0003e;T (rs851982)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">144 (53.5)</td><td align="left" rowspan="1" colspan="1">252 (57.3)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/T</bold></td><td align="left" rowspan="1" colspan="1">53 (19.7)</td><td align="left" rowspan="1" colspan="1">77 (17.5)</td><td align="left" rowspan="1" colspan="1">1.09 (0.71,1.67)</td><td align="left" rowspan="1" colspan="1">0.77 (0.40,1.46)</td><td align="left" rowspan="1" colspan="1">1.97 (0.73,5.33)</td><td align="left" rowspan="1" colspan="1">0.98 (0.58,1.66)</td><td align="left" rowspan="1" colspan="1">0.91 (0.20,4.12)</td><td align="left" rowspan="1" colspan="1">1.06 (0.70,1.60)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.03 (0.73,1.44)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">7 (2.6)</td><td align="left" rowspan="1" colspan="1">13 (3.0)</td><td align="left" rowspan="1" colspan="1">0.90 (0.33,2.47)</td><td align="left" rowspan="1" colspan="1">0.67 (0.16,2.76)</td><td align="left" rowspan="1" colspan="1">0.57 (0.06,5.28)</td><td align="left" rowspan="1" colspan="1">1.59 (0.50,5.01)</td><td align="left" rowspan="1" colspan="1">.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.88 (0.32,2.40)</td><td align="left" rowspan="1" colspan="1">1.06 (0.53,2.07)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>missing</bold></td><td align="left" rowspan="1" colspan="1">65 (24.2)</td><td align="left" rowspan="1" colspan="1">98 (22.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.884</td><td align="left" rowspan="1" colspan="1">0.360</td><td align="left" rowspan="1" colspan="1">0.584</td><td align="left" rowspan="1" colspan="1">0.654</td><td align="left" rowspan="1" colspan="1">0.607</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR1 Ex8&#x0002b;229G&#x0003e;A (rs2228480)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">77 (28.6)</td><td align="left" rowspan="1" colspan="1">136 (30.9)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">102 (37.9)</td><td align="left" rowspan="1" colspan="1">183 (41.6)</td><td align="left" rowspan="1" colspan="1">1.03 (0.70,1.53)</td><td align="left" rowspan="1" colspan="1">1.19 (0.69,2.07)</td><td align="left" rowspan="1" colspan="1">0.87 (0.38,2.03)</td><td align="left" rowspan="1" colspan="1">1.18 (0.73,1.89)</td><td align="left" rowspan="1" colspan="1">0.71 (0.15,3.38)</td><td align="left" rowspan="1" colspan="1">1.07 (0.74,1.54)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.07 (0.84,1.38)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">40 (14.9)</td><td align="left" rowspan="1" colspan="1">60 (13.6)</td><td align="left" rowspan="1" colspan="1">1.17 (0.70,1.96)</td><td align="left" rowspan="1" colspan="1">0.98 (0.47,2.03)</td><td align="left" rowspan="1" colspan="1">1.39 (0.41,4.65)</td><td align="left" rowspan="1" colspan="1">1.31 (0.70,2.46)</td><td align="left" rowspan="1" colspan="1">1.16 (0.13,9.99)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.15 (0.72,1.83)</td><td align="left" rowspan="1" colspan="1">1.14 (0.71,1.90)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Missing</bold></td><td align="left" rowspan="1" colspan="1">50 (18.6)</td><td align="left" rowspan="1" colspan="1">61(13.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.579</td><td align="left" rowspan="1" colspan="1">0.905</td><td align="left" rowspan="1" colspan="1">0.726</td><td align="left" rowspan="1" colspan="1">0.358</td><td align="left" rowspan="1" colspan="1">0.926</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR2 38 bp 3&#x02032; of STP (rs4986938) G&#x0003e;A</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">81 (30.1)</td><td align="left" rowspan="1" colspan="1">134 (30.5)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">105 (39.0)</td><td align="left" rowspan="1" colspan="1">185 (42.1)</td><td align="left" rowspan="1" colspan="1">0.95 (0.64,1.41)</td><td align="left" rowspan="1" colspan="1">0.90 (0.52,1.58)</td><td align="left" rowspan="1" colspan="1">1.41 (0.57,3.46)</td><td align="left" rowspan="1" colspan="1">0.77 (0.48,1.22)</td><td align="left" rowspan="1" colspan="1">0.89 (0.17,4.69)</td><td align="left" rowspan="1" colspan="1">0.96 (0.66,1.39)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.98 (0.76,1.27)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">33 (12.3)</td><td align="left" rowspan="1" colspan="1">51 (11.6)</td><td align="left" rowspan="1" colspan="1">0.98 (0.57,1.70)</td><td align="left" rowspan="1" colspan="1">1.08 (0.48,2.46)</td><td align="left" rowspan="1" colspan="1">2.98 (0.88,10.09)</td><td align="left" rowspan="1" colspan="1">0.78(0.41,1.51)</td><td align="left" rowspan="1" colspan="1">2.41 (0.19,31.23)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.01 (0.61,1.68)</td><td align="left" rowspan="1" colspan="1">0.96 (0.58,1.61)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>missing</bold></td><td align="left" rowspan="1" colspan="1">50 (18.6)</td><td align="left" rowspan="1" colspan="1">70 (15.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.895</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">0.090</td><td align="left" rowspan="1" colspan="1">0.330</td><td align="left" rowspan="1" colspan="1">0.637</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR2 5659 bp 3&#x02032; of STP A&#x0003e;G (rs928554)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">28 (10.4)</td><td align="left" rowspan="1" colspan="1">58 (13.2)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">117 (43.5,53.9)</td><td align="left" rowspan="1" colspan="1">193 (43.9)</td><td align="left" rowspan="1" colspan="1">1.21 (0.71,2.07)</td><td align="left" rowspan="1" colspan="1">1.17 (0.57,2.41)</td><td align="left" rowspan="1" colspan="1">2.35 (0.68,8.06)</td><td align="left" rowspan="1" colspan="1">0.95 (0.51,1.79)</td><td align="left" rowspan="1" colspan="1">1.57 (0.26,9.46)</td><td align="left" rowspan="1" colspan="1">1.19 (0.72,1.97)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.05 (0.81,1.38)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">67(24.9)</td><td align="left" rowspan="1" colspan="1">111 (25.2)</td><td align="left" rowspan="1" colspan="1">1.16 (0.66,2.03)</td><td align="left" rowspan="1" colspan="1">1.19 (0.53,2.65)</td><td align="left" rowspan="1" colspan="1">2.54 (0.75,8.60)</td><td align="left" rowspan="1" colspan="1">0.86 (0.45,1.66)</td><td align="left" rowspan="1" colspan="1">1.89 (0.24,14.87)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.01 (0.68,1.49)</td><td align="left" rowspan="1" colspan="1">1.10 (0.66,1.90)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Missing</bold></td><td align="left" rowspan="1" colspan="1">57(21.2)</td><td align="left" rowspan="1" colspan="1">78 (17.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.700</td><td align="left" rowspan="1" colspan="1">0.691</td><td align="left" rowspan="1" colspan="1">0.189</td><td align="left" rowspan="1" colspan="1">0.627</td><td align="left" rowspan="1" colspan="1">0.561</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR2 5696 bp 3&#x02032; of STP A&#x0003e;G (NA</bold><xref ref-type="table-fn" rid="nt111">&#x000a7;&#x000a7;</xref><bold>)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">181(67.3)</td><td align="left" rowspan="1" colspan="1">316 (71.8)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/G,G/G</bold><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">33(12.3)</td><td align="left" rowspan="1" colspan="1">53 (12.1)</td><td align="left" rowspan="1" colspan="1">1.04 (0.61,1.75)</td><td align="left" rowspan="1" colspan="1">1.04 (0.53,2.03)</td><td align="left" rowspan="1" colspan="1">0.82 (0.24,2.85)</td><td align="left" rowspan="1" colspan="1">1.02 (0.55,1.87)</td><td align="left" rowspan="1" colspan="1">0.75 (0.12,4.75)</td><td align="left" rowspan="1" colspan="1">1.04 (0.61,1.75)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Missing</bold></td><td align="left" rowspan="1" colspan="1">55(20.5)</td><td align="left" rowspan="1" colspan="1">71 (16.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.894</td><td align="left" rowspan="1" colspan="1">0.910</td><td align="left" rowspan="1" colspan="1">0.756</td><td align="left" rowspan="1" colspan="1">0.959</td><td align="left" rowspan="1" colspan="1">0.758</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="11" align="left" rowspan="1"><bold>ESR2 5772 bp 3&#x02032; of STP A&#x0003e;G (rs8018687)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">191 (71.0)</td><td align="left" rowspan="1" colspan="1">324 (73.6)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/G,G/G</bold><xref ref-type="table-fn" rid="nt108">&#x02021;</xref></td><td align="left" rowspan="1" colspan="1">31 (11.5)</td><td align="left" rowspan="1" colspan="1">50 (10.9)</td><td align="left" rowspan="1" colspan="1">1.07 (0.64,1.79)</td><td align="left" rowspan="1" colspan="1">1.16 (0.60,2.25)</td><td align="left" rowspan="1" colspan="1">1.05 (0.36,3.03)</td><td align="left" rowspan="1" colspan="1">1.13 (0.63,2.04)</td><td align="left" rowspan="1" colspan="1">.</td><td align="left" rowspan="1" colspan="1">1.07 (0.64,1.79)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Missing</bold></td><td align="left" rowspan="1" colspan="1">47 (17.5)</td><td align="left" rowspan="1" colspan="1">66 (15.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.550</td><td align="left" rowspan="1" colspan="1">0.650</td><td align="left" rowspan="1" colspan="1">0.928</td><td align="left" rowspan="1" colspan="1">0.684</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label>&#x0002a;</label><p>C/C: two cases and five controls in C/C genotype category.</p></fn><fn id="nt107"><label>&#x02020;</label><p>one case and two controls in G/G genotype category.</p></fn><fn id="nt108"><label>&#x02021;</label><p>three cases and two controls in G/G genotype category.</p></fn><fn id="nt109"><label>&#x000a7;</label><p>Localized&#x0200a;&#x0003d;&#x0200a;TNM stage 0,1,2; Advanced&#x0200a;&#x0003d;&#x0200a;TNM stage 3,4.</p></fn><fn id="nt110"><label>&#x0041f;</label><p>Low Grade&#x0200a;&#x0003d;&#x0200a;Grade 1,2; High Grade&#x0200a;&#x0003d;&#x0200a;Grade 3 (Grade: 1(Gleason score 2&#x02013;4, well differentiated), 2(Gleason score 5&#x02013;7, moderately differentiated), 3(Gleason score 8&#x02013;10, poorly differentiated).</p></fn><fn id="nt111"><label>&#x000a7;&#x000a7;</label><p>no data available.</p></fn><fn id="nt112"><label/><p>Blanks cells denote calculations unable to be performed due to small sizes.</p></fn></table-wrap-foot></table-wrap><p>Among the the group with low intake of phytoestrogen, men who had the variant homozygote G/G genotype in ESR1 Ex4-122C&#x0003e;G had a 5-fold increase in the odds of developing prostate cancer when compared with wild type homozygote C/C genotype (P&#x0200a;&#x0003d;&#x0200a;0.02, p-value for trend&#x0200a;&#x0003d;&#x0200a;0.04) (<xref ref-type="table" rid="pone-0006523-t003">Table 3</xref>). In contrast, men who had a variant homozygote C/C genotype in ESR1 Ex1&#x0002b;392T&#x0003e;C and G/C, C/C genotype in ESR1 Ex1-192G&#x0003e;C had a decrease in the odds of developing prostate cancer by 63&#x00025; (P&#x0200a;&#x0003d;&#x0200a;0.017, p-value for trend&#x0200a;&#x0003d;&#x0200a;0.015) and 75&#x00025; (P&#x0200a;&#x0003d;&#x0200a;0.004) compared to wild type homozygote T/T and G/G genotype, respectively (<xref ref-type="table" rid="pone-0006523-t003">Table 3</xref>).</p><table-wrap id="pone-0006523-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006523.t003</object-id><label>Table 3</label><caption><title>Estrogen receptor gene polymorphisms and prostate cancer risk according to BMI and habitual dietary intake of Phytoestrogen.</title></caption><alternatives><graphic id="pone-0006523-t003-3" xlink:href="pone.0006523.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td colspan="6" align="left" rowspan="1">Odds Ratio (95&#x00025;CI)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Overall</td><td colspan="2" align="left" rowspan="1">Phytoestrogen<xref ref-type="table-fn" rid="nt113">&#x0002a;</xref></td><td colspan="3" align="left" rowspan="1">BMI<xref ref-type="table-fn" rid="nt114">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(case/control)</td><td align="left" rowspan="1" colspan="1">Low (101/153)</td><td align="left" rowspan="1" colspan="1">High (93/152)</td><td align="left" rowspan="1" colspan="1">&#x0003c;25 (89/133)</td><td align="left" rowspan="1" colspan="1">25&#x02013;30 (141/246)</td><td align="left" rowspan="1" colspan="1">(30 (39/61)</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex4-122C&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/G</bold></td><td align="left" rowspan="1" colspan="1">1.08 (0.75,1.55)</td><td align="left" rowspan="1" colspan="1">1.32 (0.72,2.42)</td><td align="left" rowspan="1" colspan="1">1.19 (0.66,2.14)</td><td align="left" rowspan="1" colspan="1">0.71 (.38,1.35)</td><td align="left" rowspan="1" colspan="1">1.40 (0.86,2.26)</td><td align="left" rowspan="1" colspan="1">2.08 (0.71,6.05)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.73 (0.78,3.85)</td><td align="left" rowspan="1" colspan="1"><bold>5.16 (1.24,21.51)</bold></td><td align="left" rowspan="1" colspan="1">1.85 (0.51,6.80)</td><td align="left" rowspan="1" colspan="1">2.48 (0.59,10.42)</td><td align="left" rowspan="1" colspan="1">1.68 (0.36,7.76)</td><td align="left" rowspan="1" colspan="1">1.95 (0.45,8.44)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.041</bold></td><td align="left" rowspan="1" colspan="1">0.338</td><td align="left" rowspan="1" colspan="1">0.946</td><td align="left" rowspan="1" colspan="1">0.151</td><td align="left" rowspan="1" colspan="1">0.197</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex1&#x0002b;392T&#x0003e;C</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/C</bold></td><td align="left" rowspan="1" colspan="1">0.92 (0.60,1.41)</td><td align="left" rowspan="1" colspan="1">0.61 (0.32,1.18)</td><td align="left" rowspan="1" colspan="1">1.12 (0.56,2.25)</td><td align="left" rowspan="1" colspan="1">1.05 (0.51,2.17)</td><td align="left" rowspan="1" colspan="1">1.10 (0.64,1.89)</td><td align="left" rowspan="1" colspan="1">0.67 (0.23,1.91)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">0.87 (0.54,1.41)</td><td align="left" rowspan="1" colspan="1"><bold>0.37 (0.17,0.84)</bold></td><td align="left" rowspan="1" colspan="1">1.38 (0.63,3.06)</td><td align="left" rowspan="1" colspan="1">0.96 (0.44,2.08)</td><td align="left" rowspan="1" colspan="1">0.95 (0.49,1.85)</td><td align="left" rowspan="1" colspan="1">0.39 (0.09,1.03)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.015</bold></td><td align="left" rowspan="1" colspan="1">0.421</td><td align="left" rowspan="1" colspan="1">0.914</td><td align="left" rowspan="1" colspan="1">0.924</td><td align="left" rowspan="1" colspan="1">0.196</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex1-192G&#x0003e;C</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/C,C/C</bold></td><td align="left" rowspan="1" colspan="1">0.96 (0.60.1.55)</td><td align="left" rowspan="1" colspan="1"><bold>0.25 (0.10,0.64)</bold></td><td align="left" rowspan="1" colspan="1">1.32 (0.64,2.71)</td><td align="left" rowspan="1" colspan="1">0.65 (0.28,1.50)</td><td align="left" rowspan="1" colspan="1">1.16 (0.65,2.07)</td><td align="left" rowspan="1" colspan="1">0.76 (0.21,2.76)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>0.004</bold></td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.315</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">0.674</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 IVS6&#x0002b;52G&#x0003e;T</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/T</bold></td><td align="left" rowspan="1" colspan="1">1.19 (0.79,1.78)</td><td align="left" rowspan="1" colspan="1">1.20 (0.57,2.51)</td><td align="left" rowspan="1" colspan="1">1.61 (0.84,3.07)</td><td align="left" rowspan="1" colspan="1">1.88 (0.85,4.16)</td><td align="left" rowspan="1" colspan="1">1.12 (0.64,1.98)</td><td align="left" rowspan="1" colspan="1">0.65 (0.22,1.94)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">1.41 (0.44,4.49)</td><td align="left" rowspan="1" colspan="1">0.93 (0.16,5.47)</td><td align="left" rowspan="1" colspan="1">5.59 (0.37,84.23)</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">7.98 (0.73, 86.21)</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="nt115">&#x02021;</xref>NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.755</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">0.408</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">0.239</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 -104062C&#x0003e;T</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/T</bold></td><td align="left" rowspan="1" colspan="1">1.09 (0.71,1.67)</td><td align="left" rowspan="1" colspan="1">0.84 (0.43,1.66)</td><td align="left" rowspan="1" colspan="1">1.05 (0.50,2.18)</td><td align="left" rowspan="1" colspan="1">1.00 (0.49,2.03)</td><td align="left" rowspan="1" colspan="1">1.42 (0.82,2.48)</td><td align="left" rowspan="1" colspan="1">0.79 (0.24,2.57)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">0.9 (0.33,2.47)</td><td align="left" rowspan="1" colspan="1">0.67 (0.11,3.87)</td><td align="left" rowspan="1" colspan="1">1.70 (0.41,7.09)</td><td align="left" rowspan="1" colspan="1">0.76 (0.17,3.33)</td><td align="left" rowspan="1" colspan="1">1.63 (0.42,6.31)</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="nt115">&#x02021;</xref>NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.525</td><td align="left" rowspan="1" colspan="1">0.565</td><td align="left" rowspan="1" colspan="1">0.81</td><td align="left" rowspan="1" colspan="1">0.178</td><td align="left" rowspan="1" colspan="1">0.205</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex8&#x0002b;229G&#x0003e;A</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">1.03(0.70,1.53)</td><td align="left" rowspan="1" colspan="1">1.06 (0.56,2.01)</td><td align="left" rowspan="1" colspan="1">0.58 (0.31,1.08)</td><td align="left" rowspan="1" colspan="1">0.87 (0.46,1.67)</td><td align="left" rowspan="1" colspan="1">1.24 (0.74,2.08)</td><td align="left" rowspan="1" colspan="1">0.71 (0.26,1.93)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.17(0.70,1.96)</td><td align="left" rowspan="1" colspan="1">2.05 (0.92,4.58)</td><td align="left" rowspan="1" colspan="1">0.56 (0.24,1.29)</td><td align="left" rowspan="1" colspan="1">1.26 (0.54,2.92)</td><td align="left" rowspan="1" colspan="1">1.28 (0.65,2.53)</td><td align="left" rowspan="1" colspan="1">0.75 (0.18.3.15)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.115</td><td align="left" rowspan="1" colspan="1">0.101</td><td align="left" rowspan="1" colspan="1">0.146</td><td align="left" rowspan="1" colspan="1">0.418</td><td align="left" rowspan="1" colspan="1">0.585</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 38 bp 3&#x02032; of STP G&#x0003e;A</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">0.95 (0.64,1.41)</td><td align="left" rowspan="1" colspan="1">1.10 (0.59,2.06)</td><td align="left" rowspan="1" colspan="1">0.92 (0.50,1.68)</td><td align="left" rowspan="1" colspan="1">1.24 (0.65,2.39)</td><td align="left" rowspan="1" colspan="1">1.03 (0.62,1.71)</td><td align="left" rowspan="1" colspan="1"><bold>0.28 (0.09,0.86)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">0.98 (0.57,1.70)</td><td align="left" rowspan="1" colspan="1">1.42 (0.60,3.37)</td><td align="left" rowspan="1" colspan="1">1.07 (0.46,2.51)</td><td align="left" rowspan="1" colspan="1">1.35 (0.55,3.33)</td><td align="left" rowspan="1" colspan="1">0.92 (0.44,1.90)</td><td align="left" rowspan="1" colspan="1">1.17 (0.29,4.74)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.455</td><td align="left" rowspan="1" colspan="1">0.986</td><td align="left" rowspan="1" colspan="1">0.455</td><td align="left" rowspan="1" colspan="1">0.875</td><td align="left" rowspan="1" colspan="1">0.443</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 5659 bp 3&#x02032; of STP A&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">1.21 (0.71,2.07)</td><td align="left" rowspan="1" colspan="1">1.16 (0.51,2.63)</td><td align="left" rowspan="1" colspan="1">0.75 (0.32,1.78)</td><td align="left" rowspan="1" colspan="1">1.60 (0.67,3.84)</td><td align="left" rowspan="1" colspan="1">1.39 (0.65,3.00)</td><td align="left" rowspan="1" colspan="1">0.58 (0.17,1.92)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.16 (0.66,2.03)</td><td align="left" rowspan="1" colspan="1">1.14 (0.47,2.75)</td><td align="left" rowspan="1" colspan="1">1.01 (0.39,2.62)</td><td align="left" rowspan="1" colspan="1">2.54 (0.96,6.72)</td><td align="left" rowspan="1" colspan="1">1.12 (0.50,2.54)</td><td align="left" rowspan="1" colspan="1">0.58 (0.16,2.10)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.816</td><td align="left" rowspan="1" colspan="1">0.778</td><td align="left" rowspan="1" colspan="1">0.053</td><td align="left" rowspan="1" colspan="1">0.906</td><td align="left" rowspan="1" colspan="1">0.438</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 5696 bp 3&#x02032; of STP A&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/G,G/G</bold></td><td align="left" rowspan="1" colspan="1">1.04 (0.61,1.75)</td><td align="left" rowspan="1" colspan="1">1.21 (0.58,2.55)</td><td align="left" rowspan="1" colspan="1">0.51 (0.19,1.37)</td><td align="left" rowspan="1" colspan="1">1.2 (0.51,2.85)</td><td align="left" rowspan="1" colspan="1">1.07 (0.57,2.02)</td><td align="left" rowspan="1" colspan="1">0.82 (0.22,3.06)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.613</td><td align="left" rowspan="1" colspan="1">0.183</td><td align="left" rowspan="1" colspan="1">0.676</td><td align="left" rowspan="1" colspan="1">0.835</td><td align="left" rowspan="1" colspan="1">0.773</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 5772 bp 3&#x02032; of STP A&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/G,G/G</bold></td><td align="left" rowspan="1" colspan="1">1.07 (0.64,1.79)</td><td align="left" rowspan="1" colspan="1">0.63 (0.23,1.72)</td><td align="left" rowspan="1" colspan="1">1.23 (0.59,2.56)</td><td align="left" rowspan="1" colspan="1">1.03 (0.43,2.50)</td><td align="left" rowspan="1" colspan="1">1.19 (0.61,2.33)</td><td align="left" rowspan="1" colspan="1">0.98 (0.26,3.67)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>P<sub> trend</sub></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.369</td><td align="left" rowspan="1" colspan="1">0.589</td><td align="left" rowspan="1" colspan="1">0.943</td><td align="left" rowspan="1" colspan="1">0.611</td><td align="left" rowspan="1" colspan="1">0.974</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt113"><label/><p>&#x0002a;Phytoestrogen: low (n&#x0200a;&#x0003d;&#x0200a;254), high (n&#x0200a;&#x0003d;&#x0200a;245); &#x02018;Low&#x02019; and &#x02018;High&#x02019; is defined as below and above the median total phytoestrogen intake of controls, 2.71 mg/mo. Missing values were excluded from the analysis.</p></fn><fn id="nt114"><label>&#x02020;</label><p>BMI: &#x0003c;25 (n&#x0200a;&#x0003d;&#x0200a;222 ), 25&#x02013;30 (n&#x0200a;&#x0003d;&#x0200a;387), &#x02265;30 (n&#x0200a;&#x0003d;&#x0200a;100 ).</p></fn><fn id="nt115"><label>&#x02021;</label><p>NA: no applicable estimate due to small sample number.</p></fn><fn id="nt116"><label/><p>All odds ratios are adjusted for age and race.</p></fn></table-wrap-foot></table-wrap><p>Overall, there was little evidence to suggest an interaction between genotypes and BMI, except that obese men (BMI&#x02265;30 kg/m<sup>2</sup>) with heterozygote G/A genotype in ESR2 38 bp 3&#x02032; of STP G&#x0003e;A had a 72&#x00025; lower risk of prostate cancer (P&#x0200a;&#x0003d;&#x0200a;0.026), and that more A alleles in ESR2 5659 bp 3&#x02032; of STP G&#x0003e;A were associated with increased prostate cancer risk in men with BMI &#x0003c;25 kg/m<sup>2</sup> (p-value for trend&#x0200a;&#x0003d;&#x0200a;0.053). Similar results were observed when BMI of 27 or 27 kg/m<sup>2</sup> was used as the cutoff for grouping (data not shown).</p><p>In men with a T/T genotype in ESR1 Ex1&#x0002b;392T&#x0003e;C, A/A genotype in ESR1 Ex8&#x0002b;229G&#x0003e;A, and A/G or G/G genotype in ESR2 5696 bp 3&#x02032; of STP A&#x0003e;G (<xref ref-type="table" rid="pone-0006523-t004">Table 4</xref>), high phytoestrogen group had a 58&#x00025; (P&#x0200a;&#x0003d;&#x0200a;0.048), 64&#x00025; (P&#x0200a;&#x0003d;&#x0200a;0.047) and 80&#x00025; (P&#x0200a;&#x0003d;&#x0200a;0.034) lower risk of developing prostate cancer, respectively. In contrast, in men with G/C, C/C genotype in ESR1 Ex1-192G&#x0003e;C, the high phytoestrogen group had 3.3 times the odds of developing prostate cancer compared with the low phytoestrogen group (P&#x0200a;&#x0003d;&#x0200a;0.034).</p><table-wrap id="pone-0006523-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006523.t004</object-id><label>Table 4</label><caption><title>The effect of phytoestrogen<xref ref-type="table-fn" rid="nt117">&#x0002a;</xref> and BMI on the risk of prostate cancer by the genotypes of estrogen receptor gene SNPs.</title></caption><alternatives><graphic id="pone-0006523-t004-4" xlink:href="pone.0006523.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td colspan="6" align="left" rowspan="1">Odds Ratio (95&#x00025;CI)</td></tr><tr><td align="left" rowspan="1" colspan="1">(case/control)</td><td colspan="2" align="left" rowspan="1">Phytoestrogen<xref ref-type="table-fn" rid="nt117">&#x0002a;</xref></td><td colspan="4" align="left" rowspan="1">BMI<xref ref-type="table-fn" rid="nt118">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Low (101/153)</td><td align="left" rowspan="1" colspan="1">High (93/152)</td><td align="left" rowspan="1" colspan="1">&#x0003c;25 (89/133)</td><td align="left" rowspan="1" colspan="1">25&#x02013;30 (141/246)</td><td align="left" rowspan="1" colspan="1">&#x02265;30 (39/61)</td><td align="left" rowspan="1" colspan="1">P<sub> trend</sub></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Overall</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.86 (0.55,1.33)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.84 (0.59,1.19)</td><td align="left" rowspan="1" colspan="1">0.95 (0.57,1.57)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex4-122C&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.89 (0.51,1.55)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.55 (0.34,0.89)</bold></td><td align="left" rowspan="1" colspan="1">0.57 (0.28,1.15)</td><td align="left" rowspan="1" colspan="1"><bold>0.036</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.85 (0.42,1.71)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.15 (0.61,2.17)</td><td align="left" rowspan="1" colspan="1">1.52 (0.56,4.12)</td><td align="left" rowspan="1" colspan="1">0.426</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.91 (0.06,14.34)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.39 (0.05,3.03)</td><td align="left" rowspan="1" colspan="1">0.43 (0.06,2.96)</td><td align="left" rowspan="1" colspan="1">0.393</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex1&#x0002b;392T&#x0003e;C</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.42 (0.18,0.99)</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.65 (0.32,1.33)</td><td align="left" rowspan="1" colspan="1">1.10 (0.41,2.93)</td><td align="left" rowspan="1" colspan="1">0.851</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/C, C/C</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.23 (0.74,2.04)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.63 (0.41,0.98)</bold></td><td align="left" rowspan="1" colspan="1">0.56 (0.28,1.08)</td><td align="left" rowspan="1" colspan="1"><bold>0.036</bold></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex1-192G&#x0003e;C</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.64 (0.39,1.02)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.60 (0.40,0.91)</bold></td><td align="left" rowspan="1" colspan="1">0.82 (0.45,1.47)</td><td align="left" rowspan="1" colspan="1">0.166</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/C,C/C</bold><xref ref-type="table-fn" rid="nt117">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>3.30 (1.09,9.96)</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.98 (0.38,2.54)</td><td align="left" rowspan="1" colspan="1">0.79 (0.19,3.24)</td><td align="left" rowspan="1" colspan="1">0.781</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 IVS6&#x0002b;52G&#x0003e;T</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.82 (0.51,1.32)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.70 (0.46,1.07)</td><td align="left" rowspan="1" colspan="1">0.93 (0.51,1.72)</td><td align="left" rowspan="1" colspan="1">0.431</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/T</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.38 (0.53,3.55)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.39 (0.16,0.95)</bold></td><td align="left" rowspan="1" colspan="1">0.36 (0.11,1.17)</td><td align="left" rowspan="1" colspan="1"><bold>0.059</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>T/T</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="nt119">&#x02021;</xref>NA</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">2.62 (0.11,64.84)</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="nt119">&#x02021;</xref>NA</td><td align="left" rowspan="1" colspan="1">0.864</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 -104062C&#x0003e;T</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/C</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.79 (0.47,1.33)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.59 (0.37,0.93)</bold></td><td align="left" rowspan="1" colspan="1">0.85 (0.43,1.67)</td><td align="left" rowspan="1" colspan="1">0.237</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C/T, T/T</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.91 (0.38,2.19)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.86 (0.41,1.79)</td><td align="left" rowspan="1" colspan="1">0.50 (0.16,1.56)</td><td align="left" rowspan="1" colspan="1">0.271</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR1 Ex8&#x0002b;229G&#x0003e;A</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.99 (0.96,4.13)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.58 (0.31,1.09)</td><td align="left" rowspan="1" colspan="1">0.93 (0.39,2.25)</td><td align="left" rowspan="1" colspan="1">0.479</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.87 (0.47,1.63)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.82 (0.47,1.42)</td><td align="left" rowspan="1" colspan="1">0.68 (0.31,1.50)</td><td align="left" rowspan="1" colspan="1">0.318</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.34 (0.12,0.97)</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.58 (0.23,1.43)</td><td align="left" rowspan="1" colspan="1">0.50 (0.12,2.06)</td><td align="left" rowspan="1" colspan="1">0.231</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 38 bp 3&#x02032; of STP G&#x0003e;A</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.84 (0.42,1.69)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.79 (0.42,1.50)</td><td align="left" rowspan="1" colspan="1">1.33 (0.58,3.00)</td><td align="left" rowspan="1" colspan="1">0.654</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A, A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.87 (0.51,1.49)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.64 (0.40,1.02)</td><td align="left" rowspan="1" colspan="1"><bold>0.43 (0.20,0.93)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.015</bold></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 5659 bp 3&#x02032; of STP A&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.95 (0.30,3.03)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.98 (0.34,12.82)</td><td align="left" rowspan="1" colspan="1">2.22 (0.63,7.79)</td><td align="left" rowspan="1" colspan="1">0.269</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>G/A, A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.78 (0.48,1.25)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.65 (0.43,0.97)</bold></td><td align="left" rowspan="1" colspan="1">0.63 (0.33,1.19)</td><td align="left" rowspan="1" colspan="1">0.054</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 5696 bp 3&#x02032; of STP A&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.08 (0.69,1.71)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.72 (0.48,1.08)</td><td align="left" rowspan="1" colspan="1">0.83 (0.47,1.48)</td><td align="left" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/G,G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.20 (0.05,0.89)</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.56 (0.20,1.57)</td><td align="left" rowspan="1" colspan="1">0.44 (0.10,1.98)</td><td align="left" rowspan="1" colspan="1">0.227</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>ESR2 5772 bp 3&#x02032; of STP A&#x0003e;G</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/A</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.83 (0.53,1.30)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"><bold>0.66 (0.44,0.99)</bold></td><td align="left" rowspan="1" colspan="1">0.73 (0.41,1.30)</td><td align="left" rowspan="1" colspan="1">0.125</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A/G,G/G</bold></td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.47 (0.40,5.44)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.71 (0.25,2.02)</td><td align="left" rowspan="1" colspan="1">0.83 (0.20,3.41)</td><td align="left" rowspan="1" colspan="1">0.703</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt117"><label/><p>&#x0002a;For phytoestrogen, additional adjustment for total energy intake was made; all odds ratios are adjusted for age and race.</p></fn><fn id="nt118"><label>&#x02020;</label><p>Low and High is defined as below and above the median total phytoestrogen intake of controls.</p></fn><fn id="nt119"><label>&#x02021;</label><p>NA: no applicable estimate due to small sample number.</p></fn></table-wrap-foot></table-wrap><p>A higher BMI was not associated with prostate cancer risk &#x0005b;OR (95&#x00025; CI)&#x0200a;&#x0003d;&#x0200a;0.84 (0.59, 1.19) in over-weight men, and OR (95&#x00025; CI)&#x0200a;&#x0003d;&#x0200a;0.95 (0.57, 1.57) in obese men&#x0005d;. In men with certain SNPs, a trend in reductions in prostate cancer was noted with increased BMI. In particular, for men with G/A, G/G genotype in ESR2 38 bp 3&#x02032; of STP G&#x0003e;A, having a BMI of &#x02265;30 kg/m<sup>2</sup> was associated with a reduced the odds of developing prostate cancer by 57&#x00025; compared to having a BMI of &#x0003c;25 kg/m<sup>2</sup> (p-value for trend&#x0200a;&#x0003d;&#x0200a;0.01) (<xref ref-type="table" rid="pone-0006523-t004">Table 4</xref>).</p><p>An interaction association by BMI on the relationship between prostate cancer risk and ESR genotypes was suggested for ESR2 38 bp 3&#x02032; of STP G&#x0003e;A (P&#x0200a;&#x0003d;&#x0200a;0.031). Interaction association by intake level of phytoestrogen on the relationship between prostate cancer risk and ESR genotypes was suggested for both ESR1 Ex1-192G&#x0003e;C (P&#x0200a;&#x0003d;&#x0200a;0.0009) and ESR1 Ex8&#x0002b;229G&#x0003e;A (P&#x0200a;&#x0003d;&#x0200a;0.044).</p></sec><sec id="s4"><title>Discussion</title><p>In this study, there was no overall association between prostate cancer risk and genotypic and allelic frequencies of ESR1 and ESR2 SNPs. Among those who were diagnosed with advanced prostate cancer, associations between prostate cancer risk and genotypes were suggestive for four SNPs: ESR1 Ex1&#x0002b;392T&#x0003e;C, ESR1 IVS6&#x0002b;52G&#x0003e;T, ESR2 38 bp 3&#x02032; of STP G&#x0003e;A and ESR2 5659 bp 3&#x02032; of STP A&#x0003e;G. Exploratory analyses suggested potential interactions between environmental exposure (BMI/phytoestrogen), and polymorphic variations in estrogen receptor genes resulting in differential prostate cancer risks.</p><p>With respect to ESR1, eight studies have addressed the same question as the present study did. In a Japanese study, codon 10(T&#x02192;C) was associated with a 2-fold increased risk for prostate cancer (OR&#x0200a;&#x0003d;&#x0200a;2.03, 95&#x00025; CI: 1.17&#x02013;3.53) <xref ref-type="bibr" rid="pone.0006523-Tanaka1">&#x0005b;22&#x0005d;</xref>. Another study, also in Japan, reported a significant association of the T/T genotype of the PvuII site in the ESR1 (OR&#x0200a;&#x0003d;&#x0200a;3.44; 95&#x00025; CI:1.97&#x02013;5.99) <xref ref-type="bibr" rid="pone.0006523-Suzuki1">&#x0005b;23&#x0005d;</xref>. This finding was confirmed by an UK study (OR&#x0200a;&#x0003d;&#x0200a;4.65; 95&#x00025; CI:1.60&#x02013;13.49) <xref ref-type="bibr" rid="pone.0006523-Low1">&#x0005b;24&#x0005d;</xref> and an Indian study (OR&#x0200a;&#x0003d;&#x0200a;2.15, 95&#x00025; CI:1.06&#x02013;4.37) <xref ref-type="bibr" rid="pone.0006523-Sobti1">&#x0005b;25&#x0005d;</xref>. In a study in the U.S., a possible association was found between prostate cancer risk and ESR1 intronic restriction site, XbaI and PuII, but the association was not statistically significant. <xref ref-type="bibr" rid="pone.0006523-Hernndez1">&#x0005b;26&#x0005d;</xref>. Another study found an association between the AG genotype, as well as presence of the G allele within the XbaI ESR1 SNP and prostate cancer risk, but no association between the <italic>Pvu</italic>II SNP and prostate cancer in black men <xref ref-type="bibr" rid="pone.0006523-Modugno1">&#x0005b;27&#x0005d;</xref>. In a French study, variant of the GGGA polymorphism from the ESR1 was associated with an increased risk of developing prostate cancer <xref ref-type="bibr" rid="pone.0006523-CancelTassin1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Nicolaiew1">&#x0005b;29&#x0005d;</xref>. Recently, Cunningham et al. have reported null association between ESR1 SNPs: IVS1-397, g34288C/T (rs2234693), IVS1-351, g3433A/G (rs9340799), ESR1 TA repeat polymorphism and prostate risk <xref ref-type="bibr" rid="pone.0006523-Cunningham1">&#x0005b;30&#x0005d;</xref>. Conversely, McIntyre et al. observed that prostate cancer risk was greater with ESR1 (TA)<sub>24</sub> and (TA)<sub>25</sub> carriers <xref ref-type="bibr" rid="pone.0006523-McIntyre1">&#x0005b;31&#x0005d;</xref>. However, none of the SNPs mentioned above overlapped with the SNPs examined in this study.</p><p>Consistent with our study findings, Cancel-Tassin et al. (2003) reported no association between prostate cancer risk and genotypes of ESR1 Ex1&#x0002b;392T&#x0003e;C and ESR2 Ex8&#x0002b;229G&#x0003e;A <xref ref-type="bibr" rid="pone.0006523-CancelTassin1">&#x0005b;28&#x0005d;</xref>. In that study, ESR1 Ex4-122C&#x0003e;G was shown to be associated with breast cancer <xref ref-type="bibr" rid="pone.0006523-Southey1">&#x0005b;41&#x0005d;</xref> and the progression of prostate cancer <xref ref-type="bibr" rid="pone.0006523-Medeiros1">&#x0005b;42&#x0005d;</xref>, which is commensurate with our findings of higher risk for being diagnosed to have advanced disease. However, the authors did not find an association with prostate cancer incidence. In addition, Medeiros et al. (2003) reported a link of ESR1 Ex4-122C&#x0003e;G to unfavorable outcome parameters such as high pathologic grade and clinical stage <xref ref-type="bibr" rid="pone.0006523-Medeiros1">&#x0005b;42&#x0005d;</xref>, a finding consistent with ours that clinical stage was associated with the genotypes of ESR1 Ex4-122C&#x0003e;G (p value from chi-square test&#x0200a;&#x0003d;&#x0200a;0.05).</p><p>Four previous studies have been published regarding association between polymorphisms in ESR2 and prostate cancer risk. One study was conducted in China, and the genotype and allele frequency of rs3829768 (A/G) and rs1271572 (C/A) in the upstream region of proximal promoter was significantly lower in prostate cancer cases than controls (P&#x0003c;0.01) <xref ref-type="bibr" rid="pone.0006523-Sun1">&#x0005b;32&#x0005d;</xref>. The other study was conducted in Sweden with findings that genotype and allele frequency of rs2987983 (T/C) in the promoter region was associated with prostate cancer risk <xref ref-type="bibr" rid="pone.0006523-ThellenbergKarlsson1">&#x0005b;33&#x0005d;</xref>, and that the protective effect of phytoestrogen on prostate cancer was significant among men with carriers homozygous for the wild type allele (TT) of the same SNP <xref ref-type="bibr" rid="pone.0006523-Hedelin1">&#x0005b;34&#x0005d;</xref>. Of recent, two studies have reported null association between ESR2 CA repeat polymorphism and prostate cancer <xref ref-type="bibr" rid="pone.0006523-Cunningham1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-McIntyre1">&#x0005b;31&#x0005d;</xref>. In a French study, additional 14 ESR2 SNPs were noted to have no association with prostate cancer risk <xref ref-type="bibr" rid="pone.0006523-Nicolaiew1">&#x0005b;29&#x0005d;</xref>. Consistent with our findings, Cunningham et al. <xref ref-type="bibr" rid="pone.0006523-Cunningham1">&#x0005b;30&#x0005d;</xref> observed null association between ESR2 3&#x02032;togene, g.49888G/A (rs4986938). Except for this one study <xref ref-type="bibr" rid="pone.0006523-Cunningham1">&#x0005b;30&#x0005d;</xref>, previous studies have not reported on the SNPs included in the present study. For example, while a study in Sweden investigated four SNPs in the promoter region and introns of ESR2, the SNPs examined in this study were in the downstream non-coding region of ESR2 <xref ref-type="bibr" rid="pone.0006523-ThellenbergKarlsson1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Hedelin1">&#x0005b;34&#x0005d;</xref>.</p><p>A few epidemiological studies supported the hypothesis of a protective association between phytoestrogen (isoflavone) intake and prostate and breast cancers <xref ref-type="bibr" rid="pone.0006523-Adlercreutz1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Lee1">&#x0005b;21&#x0005d;</xref>. Our study, however, did not show overall protective association of phytoestrogen intake for prostate cancer but did find a suggested interaction with two ESR1 SNPs (rs746432, rs2228480). Swedish study has identified rs2987983 in the promoter region of ESR2, which was not included in our study, as a potential effect modifier in the relationship between the intake of phytoestrogen and the risk of prostate cancer <xref ref-type="bibr" rid="pone.0006523-Hedelin1">&#x0005b;34&#x0005d;</xref>. Two aspects of the data on phytoestrogen intake should be noted. First, missing data may have compromised the validity for assessing the association between phytoestrogen consumption and prostate cancer risk. In CLUE II, the food frequency questionnaire did not include soy beans or soy products such as soy milk and tofu. However, these are not expected to be a predominant source of phytoestrogens in this population. Furthermore, at the time of the CLUE study enrollment in 1989, soy products were not prevalent in the American diet. This study estimated the amount of phytoestrogen (isoflavone) intake by summing up the intakes of three legume items (beans, peas, peanuts), which were the predominant sources of phytoestrogen in the American diet. In summing the intakes of legume items, since missing one item led to missing data on the sum of all items, the proportion of missing data went up to around 30&#x00025;. A high proportion of missing data significantly decreases the sample size available for statistical analysis, and consequently decreases statistical power. However, in imputation analysis, inserting zero or median in place of missing data did not affect the overall results. Second, the amount of phytoestrogen consumed in the Washington County was much less than that in Southeast Asia where soy is consumed habitually in moderate to large quantity. This may be one of the reasons that explained the discrepancies found between studies in Asia and the present study <xref ref-type="bibr" rid="pone.0006523-Lee1">&#x0005b;21&#x0005d;</xref>.</p><p>With regard to the test for interactive effects, the significance level (type I error rate) is the probability of falsely reporting significant interaction. Assuming the same effects across strata, the probability of finding at least one significant interaction by chance alone when undertaking 20 independent subgroup analyses such as in <xref ref-type="table" rid="pone-0006523-t004">table 4</xref> is 65&#x00025; <xref ref-type="bibr" rid="pone.0006523-Lagakos1">&#x0005b;43&#x0005d;</xref>. When the corrected p value for over-inflated false positive rate <xref ref-type="bibr" rid="pone.0006523-Huang1">&#x0005b;44&#x0005d;</xref>, 0.0025 (0.05&#x000f7;20), is applied to <xref ref-type="table" rid="pone-0006523-t004">table 4</xref>, one interaction remains statistically significant: with ESR1 Ex1-192G&#x0003e;C (log likelihood ratio test: p&#x0200a;&#x0003d;&#x0200a;0.0009&#x0003c;0.0025), suggesting that this SNP was a strong effect modifier on the association between dietary intake of phytoestrogen and prostate cancer risk.</p><p>A major limitation of this study is that only a subset of known SNPs in two genes, ESR1 and ESR2, were examined:. Only 3 out of 10 selected SNPs (ESR1 Ex1&#x0002b;392T&#x0003e;C, ESR2 Ex8&#x0002b;229G&#x0003e;A, and ESR1 Ex4-122C&#x0003e;G) were studied in the past <xref ref-type="bibr" rid="pone.0006523-CancelTassin1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006523-Medeiros1">&#x0005b;42&#x0005d;</xref>, where null associations with prostate cancer risk were observed, consistent with our study findings. However, for the other 7 SNPs selected, our group was the first to report no overall association between those SNPs and prostate cancer incidence.</p><p>Functions of all candidate SNPs remain unclear. All of the four ESR1 SNPs in exons were synonymous polymorphisms with no associated amino acid change. Therefore, it is unlikely that these polymorphisms are causative. Yet, they may be in linkage disequilibrium with an unknown causative variant. Or, they can cause a structural change in RNA, altering translation efficacy, and thereby, leading to a change in ESR1 gene expression rate <xref ref-type="bibr" rid="pone.0006523-Tanaka1">&#x0005b;22&#x0005d;</xref>. The situation is the same for other SNPs either in non-coding regions or in introns, warranting further functional or expression studies.</p><p>Tests of prostate-specific antigen (PSA) have been increasingly used for screening and diagnosis of prostate cancer since early 1990s. Differential use of PSA test between cases and controls may result in detection bias. In this study, there was no evidence of over-diagnoses of early cancer using PSA tests and digital rectal examinations (DRE) <xref ref-type="bibr" rid="pone.0006523-Huang1">&#x0005b;44&#x0005d;</xref>. No appreciable difference in PSA test rate between cases and controls was observed. We had few African Americans and no Asians in the cohort, so we did not examine the associations in various ethnic groups.</p><p>In summary, no overall statistically significant association between prostate cancer risk and the selected ten SNPs in ESR1 and ESR2 genes was observed. However, four SNPs (rs2077647, rs2273206, rs4986938, rs928554) may be linked with higher risk for being diagnosed to have advanced stage disease. In addition, there may be an interactive effect between BMI/phytoestrogen and ESR genotypes on the risk of prostate cancer. Further investigations are needed to see if the study is replicable in other populations, especially in other ethnic groups, and to find out how the gene-environment interaction can be explained under the biological models.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0006523.s001"><label>Table S1</label><caption><p>Hardy Weinberg Equilibrium (HWE) among Caucasian cases and controls</p><p>(0.02 MB XLS)</p></caption><media xlink:href="pone.0006523.s001.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0006523.s002"><label>Table S2</label><caption><p>Observed estrogen receptor SNP frequency in CLUE controls and SNP500/dbSNP data by race</p><p>(0.02 MB XLS)</p></caption><media xlink:href="pone.0006523.s002.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the staff members in the George W. Comstock Center for Public Health Research and Prevention for their assistance in data collection and data management. We also thank Grace Chan (Children's Hospital Boston) for her help in analyzing phytoestrogen intake analysis and Jung Eun Lee (Harvard School of Public Health) for her assistance in revising and proofreading the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0006523-Gann1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gann</surname><given-names>PH</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname> Longcope</surname><given-names>C</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name></person-group><year>1996</year><article-title>Prospective study of sex hormone levels and risk of prostate cancer.</article-title><source>J Natl Cancer Inst</source><volume>88</volume><fpage>1118</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">8757191</pub-id></mixed-citation></ref><ref id="pone.0006523-Ekman1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>P</given-names></name></person-group><year>2000</year><article-title>The Prostate as an endocrine organ: androgens and estrogens.</article-title><source>Prostate</source><volume>10</volume><issue>Suppl</issue><fpage>14</fpage><lpage>18</lpage></mixed-citation></ref><ref id="pone.0006523-Noble1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>RL</given-names></name></person-group><year>1977</year><article-title>The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration.</article-title><source>Cancer Research</source><volume>37</volume><fpage>1929</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">858144</pub-id></mixed-citation></ref><ref id="pone.0006523-Singer1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>EA</given-names></name><name><surname>Golijanin</surname><given-names>DJ</given-names></name><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Messing</surname><given-names>EM</given-names></name></person-group><year>2008</year><article-title>Androgen deprivation therapy for prostate cancer.</article-title><source>Expert Opin Pharmacother</source><volume>9(2)</volume><fpage>211</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">18201145</pub-id></mixed-citation></ref><ref id="pone.0006523-Ricke1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricke</surname><given-names>WA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cunha</surname><given-names>GR</given-names></name></person-group><year>2007</year><article-title>Steroid hormones and carcinogenesis of the prostate: the role of estrogens.</article-title><source>Differentiation</source><volume>75(9)</volume><fpage>871</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">17924963</pub-id></mixed-citation></ref><ref id="pone.0006523-Kuiper1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M</given-names></name></person-group><year>1996</year><article-title>Cloning of a novel receptor expressed in rat prostate and ovary.</article-title><source>Proc Natl Acad Sci USA</source><volume>93</volume><fpage>5925</fpage><lpage>5930</lpage><pub-id pub-id-type="pmid">8650195</pub-id></mixed-citation></ref><ref id="pone.0006523-Mosselman1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosselman</surname><given-names>S</given-names></name><name><surname>Polman</surname><given-names>J</given-names></name><name><surname>Dijkema</surname><given-names>R</given-names></name></person-group><year>1996</year><article-title>ER beta: identification and characterization of a novel human estrogen receptor.</article-title><source>FEBS Lett</source><volume>392</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">8769313</pub-id></mixed-citation></ref><ref id="pone.0006523-Kuiper2"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Carlsson</surname><given-names>B</given-names></name><name><surname>Grandien</surname><given-names>K</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>H&#x000e4;ggblad</surname><given-names>J</given-names></name><etal/></person-group><year>1997</year><article-title>Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.</article-title><source>Endocrinology</source><volume>138</volume><fpage>863</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9048584</pub-id></mixed-citation></ref><ref id="pone.0006523-Bashirelahi1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashirelahi</surname><given-names>N</given-names></name><name><surname>Kneussl</surname><given-names>ES</given-names></name><name><surname>Vassil</surname><given-names>TC</given-names></name><name><surname>Young</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name><surname>Sanefugi</surname><given-names>H</given-names></name><etal/></person-group><year>1979</year><article-title>Measurement and characterization of estrogen receptors in the human prostate.</article-title><source>Prog Clin Biol Res</source><volume>33</volume><fpage>65</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">93752</pub-id></mixed-citation></ref><ref id="pone.0006523-Prins1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>GS</given-names></name><name><surname>Marmer</surname><given-names>M</given-names></name><name><surname>Woodham</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Kuiper</surname><given-names>G</given-names></name><etal/></person-group><year>1998</year><article-title>Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats.</article-title><source>Endocrinology</source><volume>139</volume><fpage>874</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">9492016</pub-id></mixed-citation></ref><ref id="pone.0006523-Yager1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yager</surname><given-names>JD</given-names></name></person-group><year>2000</year><article-title>Endogenous estrogens as carcinogens through metabolic activation.</article-title><source>J Natl Cancer Inst Monogr</source><volume>27</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">10963620</pub-id></mixed-citation></ref><ref id="pone.0006523-Risbridger1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risbridger</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>P</given-names></name><name><surname>Kurita</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><etal/></person-group><year>2001</year><article-title>Evidence that epithelial and mesenchymal estrogen receptor-&#x003b1; mediates effects of estrogen on prostatic epithelium.</article-title><source>Dev Biol</source><volume>229</volume><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">11150243</pub-id></mixed-citation></ref><ref id="pone.0006523-Fujimura1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Urano</surname><given-names>T</given-names></name><name><surname>Kumagai</surname><given-names>J</given-names></name><name><surname>Ogushi</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Increased expression of estrogen-related receptor alpha (ERR alpha) is a negative prognostic predictor in human prostate cancer.</article-title><source>Int J Cancer</source><volume>120</volume><fpage>2325</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">17294452</pub-id></mixed-citation></ref><ref id="pone.0006523-Koehler1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koehler</surname><given-names>KF</given-names></name><name><surname>Helguero</surname><given-names>LA</given-names></name><name><surname>Haldos&#x000e9;n</surname><given-names>LA</given-names></name><name><surname>Warner</surname><given-names>M</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><etal/></person-group><year>2005</year><article-title>Reflections on the discovery and significance of estrogen receptor &#x003b2;.</article-title><source>Endocr Rev</source><volume>26</volume><fpage>465</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">15857973</pub-id></mixed-citation></ref><ref id="pone.0006523-Signoretti1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>Estrogen receptor &#x003b2; in prostate cancer: brake pedal or accelerator?</article-title><source>Am J Pathol</source><volume>159</volume><fpage>13</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11438447</pub-id></mixed-citation></ref><ref id="pone.0006523-Prins2"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>GS</given-names></name><name><surname>Birch</surname><given-names>L</given-names></name><name><surname>Couse</surname><given-names>JF</given-names></name><name><surname>Choi</surname><given-names>I</given-names></name><name><surname>Katzenellenbogen</surname><given-names>B</given-names></name><etal/></person-group><year>2001</year><article-title>Estrogen Imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha.</article-title><source>Cancer Res</source><volume>61</volume><fpage>6089</fpage><lpage>6097</lpage><pub-id pub-id-type="pmid">11507058</pub-id></mixed-citation></ref><ref id="pone.0006523-Leav1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leav</surname><given-names>I</given-names></name><name><surname>Lau</surname><given-names>KM</given-names></name><name><surname>Adams</surname><given-names>JY</given-names></name><name><surname>McNeal</surname><given-names>JE</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><etal/></person-group><year>2001</year><article-title>Comparative studies of the estrogen receptors &#x003b2; and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.</article-title><source>Am J Pathol</source><volume>159</volume><fpage>79</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11438457</pub-id></mixed-citation></ref><ref id="pone.0006523-Zhu1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Leav</surname><given-names>I</given-names></name><name><surname>Leung</surname><given-names>YK</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><year>2004</year><article-title>Dynamic regulation of estrogen receptor-&#x003b2; expression by DNA methylation during prostate cancer development and metastasis.</article-title><source>Am J Pathol</source><volume>164</volume><fpage>2003</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">15161636</pub-id></mixed-citation></ref><ref id="pone.0006523-Lai1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>LG</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Hawley</surname><given-names>SJ</given-names></name><name><surname>Etzioni</surname><given-names>RB</given-names></name><etal/></person-group><year>2004</year><article-title>Metastases of prostate cancer express estrogen receptor-&#x003b2;.</article-title><source>Urology</source><volume>64</volume><fpage>814</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">15491740</pub-id></mixed-citation></ref><ref id="pone.0006523-Adlercreutz1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adlercreutz</surname><given-names>H</given-names></name><name><surname>Mazur</surname><given-names>W</given-names></name></person-group><year>1997</year><article-title>Phytoestrogens and Western diseases.</article-title><source>Ann Med</source><volume>29</volume><fpage>95</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">9187225</pub-id></mixed-citation></ref><ref id="pone.0006523-Lee1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MM</given-names></name><name><surname>Gomez</surname><given-names>SL</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Wey</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>RT</given-names></name><etal/></person-group><year>2003</year><article-title>Soy and isoflavone consumption in relation to prostate cancer risk in China.</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>12(7)</volume><fpage>665</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12869409</pub-id></mixed-citation></ref><ref id="pone.0006523-Tanaka1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Kaneuchi</surname><given-names>M</given-names></name><name><surname>Shiina</surname><given-names>H</given-names></name><name><surname>Igawa</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Polymorphisms of estrogen receptor alpha in prostate cancer.</article-title><source>Mol Carcinog</source><volume>37(4)</volume><fpage>202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12891629</pub-id></mixed-citation></ref><ref id="pone.0006523-Suzuki1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Nakazato</surname><given-names>H</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Koike</surname><given-names>H</given-names></name><name><surname>Okugi</surname><given-names>H</given-names></name><etal/></person-group><year>2003</year><article-title>Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.</article-title><source>Cancer</source><volume>98(7)</volume><fpage>1411</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14508827</pub-id></mixed-citation></ref><ref id="pone.0006523-Low1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>YL</given-names></name><name><surname>Taylor</surname><given-names>JI</given-names></name><name><surname>Grace</surname><given-names>PB</given-names></name><name><surname>Mulligan</surname><given-names>AA</given-names></name><name><surname>Welch</surname><given-names>AA</given-names></name><etal/></person-group><year>2006</year><article-title>Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk.</article-title><source>Nutr Cancer</source><volume>56(1)</volume><fpage>31</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17176215</pub-id></mixed-citation></ref><ref id="pone.0006523-Sobti1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobti</surname><given-names>RC</given-names></name><name><surname>Gupta</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name><etal/></person-group><year>2008</year><article-title>Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.</article-title><source>Cancer Genet Cytogenet</source><volume>185(2)</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">18722876</pub-id></mixed-citation></ref><ref id="pone.0006523-Hernndez1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>J</given-names></name><name><surname>Balic</surname><given-names>I</given-names></name><name><surname>Johnson-Pais</surname><given-names>TL</given-names></name><name><surname>Higgins</surname><given-names>BA</given-names></name><name><surname>Torkko</surname><given-names>KC</given-names></name><etal/></person-group><year>2006</year><article-title>Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men.</article-title><source>J Urol</source><volume>175(2)</volume><fpage>523</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16406987</pub-id></mixed-citation></ref><ref id="pone.0006523-Modugno1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modugno</surname><given-names>F</given-names></name><name><surname>Weissfeld</surname><given-names>JL</given-names></name><name><surname>Trump</surname><given-names>DL</given-names></name><name><surname>Zmuda</surname><given-names>JM</given-names></name><name><surname>Shea</surname><given-names>P</given-names></name></person-group><year>2001</year><article-title>et al. Allelic Varients of Aromatase and Androgen and Estrogen Receptors: Toward a Multigenetic Model of Prostate Cancer Risk.</article-title><source>Clinical Cancer Research</source><volume>7</volume><fpage>3092</fpage><lpage>3096</lpage><pub-id pub-id-type="pmid">11595700</pub-id></mixed-citation></ref><ref id="pone.0006523-CancelTassin1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Latil</surname><given-names>A</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Mangin</surname><given-names>P</given-names></name><name><surname>Bottius</surname><given-names>E</given-names></name><etal/></person-group><year>2003</year><article-title>Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk.</article-title><source>Eur Urol</source><volume>44(4)</volume><fpage>487</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">14499686</pub-id></mixed-citation></ref><ref id="pone.0006523-Nicolaiew1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolaiew</surname><given-names>N</given-names></name><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Azzouzi</surname><given-names>AR</given-names></name><name><surname>Legrand</surname><given-names>B</given-names></name><name><surname>Mangin</surname><given-names>P</given-names></name><etal/></person-group><year>2008</year><article-title>Association between estrogen and androgen receptor genes and prostate cancer risk.</article-title><source>Eur J Endocrinol</source><comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1530/EJE-08-0321">10.1530/EJE-08-0321</ext-link></comment></mixed-citation></ref><ref id="pone.0006523-Cunningham1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>JM</given-names></name><name><surname>Hebbring</surname><given-names>SJ</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><etal/></person-group><year>2007</year><article-title>Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>16(5)</volume><fpage>969</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">17507624</pub-id></mixed-citation></ref><ref id="pone.0006523-McIntyre1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>MH</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><etal/></person-group><year>2007</year><article-title>Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms.</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>16(11)</volume><fpage>2233</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18006911</pub-id></mixed-citation></ref><ref id="pone.0006523-Sun1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YH</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><etal/></person-group><year>2005</year><article-title>Association between single-nucleotide polymorphisms in estrogen receptor beta gene and risk of prostate cancer.</article-title><source>Zhonghua Wai Ke Za Zhi</source><volume>43(14)</volume><fpage>948</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16083630</pub-id></mixed-citation></ref><ref id="pone.0006523-ThellenbergKarlsson1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thellenberg-Karlsson</surname><given-names>C</given-names></name><name><surname>Lindstrom</surname><given-names>S</given-names></name><name><surname>Malmer</surname><given-names>B</given-names></name><etal/></person-group><year>2006</year><article-title>Estrogen receptor beta polymorphism is associated with prostate cancer risk.</article-title><source>Clin Cancer Res</source><volume>15</volume><fpage>306</fpage><lpage>11</lpage></mixed-citation></ref><ref id="pone.0006523-Hedelin1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedelin</surname><given-names>M</given-names></name><name><surname>Balter</surname><given-names>KA</given-names></name><name><surname>Chang</surname><given-names>ET</given-names></name><etal/></person-group><year>2006</year><article-title>Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.</article-title><source>Prostate</source><volume>66(14)</volume><fpage>1512</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16921512</pub-id></mixed-citation></ref><ref id="pone.0006523-Schneider1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Kirschner</surname><given-names>MA</given-names></name><name><surname>Berkowitz</surname><given-names>R</given-names></name><etal/></person-group><year>1979</year><article-title>Increased estrogen production in obese men.</article-title><source>J Clin Endocrinol Metab</source><volume>48</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">429508</pub-id></mixed-citation></ref><ref id="pone.0006523-Kuiper3"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><year>1997</year><article-title>The novel estrogen receptor-&#x003b2; subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens.</article-title><source>FEBS Lett</source><volume>410</volume><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9247129</pub-id></mixed-citation></ref><ref id="pone.0006523-The1"><label>37</label><mixed-citation publication-type="other"><collab>The George W</collab><article-title>Comstock Center for Public Health Research and Prevention &#x0005b;homepage on the Internet&#x0005d;. Maryland: 2002, The Johns Hopkins Bloomberg School of Public Health &#x0005b;updated 2002; cited 2008 Feb 28&#x0005d;.</article-title><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.jhsph.edu/comstockcenter/pdf/CLUE_II_FFQ.pdf">http://www.jhsph.edu/comstockcenter/pdf/CLUE_II_FFQ.pdf</ext-link></comment></mixed-citation></ref><ref id="pone.0006523-Packer1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>BR</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Staats</surname><given-names>B</given-names></name><etal/></person-group><article-title>SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes.</article-title><source>Nucleic Acids Res</source><volume>2004; 32(Database issue)</volume><fpage>D528</fpage><lpage>D532</lpage></mixed-citation></ref><ref id="pone.0006523-denDunnen1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Dunnen</surname><given-names>JT</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name></person-group><year>2001</year><article-title>Nomenclature for the description of human sequence variations.</article-title><source>Hum Genet</source><volume>109(1)</volume><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">11479744</pub-id></mixed-citation></ref><ref id="pone.0006523-1"><label>40</label><mixed-citation publication-type="other"><article-title>USDA-Iowa State University Database on the Isoflavone Content of Foods &#x0005b;homepage on the Internet&#x0005d;. U.S. Department of Agriculture, Agricultural Research Service. &#x0005b;updated 2004 Oct 25; cited 2008 Feb 28&#x0005d;.</article-title><comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.nal.usda.gov/fnic/foodcomp/Data/isoflav/isfl_tbl.pdf">http://www.nal.usda.gov/fnic/foodcomp/Data/isoflav/isfl_tbl.pdf</ext-link></comment></mixed-citation></ref><ref id="pone.0006523-Southey1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>Batten</surname><given-names>LE</given-names></name><name><surname>McCredie</surname><given-names>MR</given-names></name><etal/></person-group><year>1998</year><article-title>Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty.</article-title><source>J Natl Cancer Inst</source><volume>90(7)</volume><fpage>532</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9539249</pub-id></mixed-citation></ref><ref id="pone.0006523-Medeiros1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros</surname><given-names>R</given-names></name><name><surname>Vasconcelos</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer.</article-title><source>Cancer Genet Cytogenet</source><volume>141(2)</volume><fpage>91</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12606125</pub-id></mixed-citation></ref><ref id="pone.0006523-Lagakos1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagakos</surname><given-names>SW</given-names></name></person-group><year>2006</year><article-title>Challenges of subgroup analysis.</article-title><source>N Engl J Med</source><volume>354(16)</volume><fpage>1667</fpage><lpage>1668</lpage><pub-id pub-id-type="pmid">16625007</pub-id></mixed-citation></ref><ref id="pone.0006523-Huang1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>HY</given-names></name><name><surname>Alberg</surname><given-names>AJ</given-names></name><name><surname>Norkus</surname><given-names>EP</given-names></name><etal/></person-group><year>2003</year><article-title>Prospective Study of Antioxidant Micronutrients in the Blood and the Risk of Developing Prostate Cancer.</article-title><source>Am J Epidemiol</source><volume>157</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">12578804</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was supported in part by the Research grant 1U01AG18033 (the National Institute on Aging). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>